

INTRODUCTION AND STUDY OBJECTIVE

- Nearly half of adolescents who vape nicotine are seriously interested in quitting, yet extant cessation interventions have received little empirical investigation.
- An ideal vaping cessation treatment must directly target established vaping risk factors, such as depression, and be highly accessible.
- **Study Objective:** 1) develop a self-directed digital health intervention (“VapeX”) incorporating Behavioral Activation (BA) to address depressive symptoms and promote vaping cessation among older adolescents, 2) evaluate intervention feasibility, and 3) describe preliminary efficacy

METHOD


- **Sample:** N=94, 70% Female, Age (M(SD)=18.7(0.9)). Half of participants (N=49) were assigned to use the VapeX app.
- VapeX uses BA methods (goal setting, activity scheduling, mood rating) with the aim to reduce depressive symptoms and promote vaping cessation.
- Participants were recruited remotely and were eligible if between the ages of 16-20, vaping daily, and currently experiencing elevated symptoms of depression (BDI-II).
- Participant data was collected once a week for 4 weeks, evaluating vaping frequency, symptoms of depression, and app usability. App usage was assessed via passively collected app analytics data.
- Data were analyzed for app usage, retention across weeks, and usability (SUS) as well as self-reported changes in vaping and depressive scores (BDI-II).

SAMPLE DEMOGRAPHICS & BASELINE VALUES

Characteristic	Full Sample (N=94)	VapeX (N=49)	Treatment as Usual (N=45)
Sex n(% Female)	66 (70)	32 (65)	34 (76)
Age (M(SD))	18.74 (0.88)	18.76 (0.92)	18.73 (0.84)
Race n(%)			
American Indian/Alaska Native	2 (2)	1 (2)	1 (2)
Asian	1 (1)	0 (0)	1 (2)
Black or African American	8 (9)	4 (8)	4 (9)
White (Caucasian)	75 (80)	38 (78)	37 (82)
Multiracial	6 (6)	4 (8)	2 (4)
Other	2 (2)	2 (4)	0 (0)
Ethnicity n(% Hispanic or Latino)	12 (13)	4 (8)	8 (18)
Highest level of education n(%)			
≤ High School diploma	52 (55)	26 (53)	26 (58)
> High School diploma	42 (45)	23 (47)	19 (42)
Employment status n(%)			
Unemployed	11 (12)	8 (16)	3 (7)
Employed full time	15 (16)	8 (16)	7 (16)
Employed part time	31 (33)	14 (29)	17 (38)
Student	34 (36)	18 (37)	16 (36)
Other	3 (3)	1 (2)	2 (4)
Total family/household income n(%)			
Less than \$50,000	40 (43)	22 (45)	18 (40)
\$50,000 or more	54 (57)	27 (55)	27 (60)
Type of smartphone n(%)			
iPhone	87 (93)	45 (92)	42 (93)
Android	7 (7)	4 (8)	3 (7)
Vapes per day (M(SD))	19.54 (23.39)	19.22 (25.14)	19.90 (21.60)
Motivation to quit vaping (M(SD))	7.43 (2.25)	7.67 (1.99)	7.22 (2.51)
E-cig dependence (Penn State ECDI) (M(SD))	11.66 (3.13)	11.61 (3.00)	11.71 (3.29)
BDI-II (M(SD))	30.65 (9.21)	30.59 (10.30)	30.71 (7.96)


Sample Demographics and Baseline Values

APP VISUALS



VapeX App Screenshots

APP ENGAGEMENT & USABILITY RESULTS




VapeX App Retention by Week

App Engagement	M(SD)
Total App Sessions	16.8(11.9)
Total Time Using App (mins)	23.9(18.1)
Goals Created	2.0(2.0)
Activities Created	2.8(3.3)
Activities Scheduled	9.2(20.7)
System Usability Scale Score at Week 4	78.7(16.98)


VapeX Overall Engagement

- Retention for app use remained high throughout the study duration starting at 100% during Week 1 and finishing at 69% by Week 4.
- On average, VapeX users engaged in nearly 17 app sessions across the 4-week period using the app for an average of about 24 minutes total (Table 1).
- BA components were used to create an average of 2.0 goals and 2.8 activities. An average of 9.2 activities were scheduled in the app.
- Scores on the System Usability Scale (SUS) showed a consistent score of 78-81 throughout the study. At Week 4 the SUS score was 78.7, showing near excellent usability among participants.

MAIN OUTCOMES



Clinical Outcomes



Mean BDI

- 59% of VapeX (56% TAU) participants made a vaping quit attempt during trial duration.
- 43% of VapeX (40% TAU) participants reduced their vaping by at least 50%.
- 14% of VapeX (11% TAU) participants reported complete abstinence for a 7-day period during trial duration.
- 41% of VapeX (36% TAU) participants reported less than minimal symptoms of depression during follow-up.
- Mean scores of the BDI-II decreased on average 8.67 (9.69) for VapeX group and 8.30 (9.97) for the TAU group.

CONCLUSIONS

- Outcomes of this trial were strong from a usability lens. VapeX demonstrated near excellent usability among participants assigned to the app condition.
- Retention was strong across all 4-weeks of the study duration showing that users are willing to engage with the intervention.
- To bolster efficacy, future app modifications may focus on enhancing engagement with BA components of VapeX, including goal setting, activity scheduling, and activity completion.
- While this trial was not powered for efficacy, vaping and depression outcomes numerically (but not statistically) favored the VapeX group. A larger, full-powered study with a refined treatment is warranted.

ACKNOWLEDGEMENTS

This work was supported by NIH grant R41 DA053856 (PI: Dahne)